Last reviewed · How we verify

NCT06339229

Postoperative New-onset Proteinuria and Adverse Outcomes.

Completed Last updated 1 April 2024
What this trial tests

trial testing proteinuria in Surgery in 2,983,899 participants. Completed in 1 November 2023.

Timeline
1 January 2000
Primary endpoint
31 December 2022
1 November 2023

Quick facts

Lead sponsorYaozhong Kong
StatusCompleted
Study typeOBSERVATIONAL
Enrollment2,983,899
Start date1 January 2000
Primary completion31 December 2022
Estimated completion1 November 2023

Drugs / interventions tested

Conditions studied

Sponsor

Yaozhong Kong

Who can join

16 and older, any sex, with Surgery or Proteinuria. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We aimed to assess the association between postoperative new-onset proteinuria, all-cause mortality, and decline in kidney function in Chinese people who underwent surgery. The exposure variable was the dipstick proteinuria values from the initial postoperative urinalysis within 30 days after surgery, categorized as negative, trace, 1+, and ≥2+. The primary outcome was 30-day mortality. The secondary outcomes included 1-year mortality and composite kidney outcome assessed using the postoperative estimated glomerular filtration rate.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of proteinuria

Trials testing the same drug.

Other recruiting trials for Surgery

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06339229.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing